By Fineline Cube Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful completion of the first clinical study of its iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system. Post-operative echocardiography confirmed complete resolution of tricuspid regurgitation with zero paravalvular leak, and the implanted LuX-Valve Plus prosthetic valve demonstrated secure anchoring and excellent hemodynamic stability. The milestone marks a critical step toward addressing one of cardiology’s most challenging unmet needs: minimally invasive treatment for severe tricuspid regurgitation.
Procedural & Clinical Outcomes
| Outcome | Result |
|---|---|
| Tricuspid Regurgitation Post-Op | Resolved (Grade 0) |
| Paravalvular Leak | None detected |
| Valve Stability | Securely anchored; no migration |
| Device Used | LuX-Valve Plus + iJensRobo robotic platform |
The case demonstrated the feasibility of robot-enhanced precision in a procedure historically limited by anatomical complexity and lack of dedicated devices.
iJensRobo Platform: Engineering Innovation
The iJensRobo system integrates three core technologies to overcome traditional TTVR challenges:
- High-Precision Motion Control: Sub-millimeter actuation enables fine adjustment during valve deployment
- Active Safety Constraints: Real-time force feedback prevents excessive tissue trauma or device malposition
- Intelligent Navigation: Fusion of fluoroscopy and 3D echocardiography guides catheter trajectory and valve orientation
Unlike general-purpose surgical robots, iJensRobo is purpose-built for transcatheter structural heart interventions, offering cardiologists enhanced dexterity without abandoning percutaneous access.
Market Context & Unmet Need
- Tricuspid Regurgitation Burden: Affects >1.6 million patients in the U.S. and EU; severe cases carry >50% 1-year mortality if untreated
- Therapeutic Gap: Few dedicated TTVR devices approved globally; most rely on off-label use or complex surgical repair
- Jenscare’s Edge: Combines its LuX-Valve Plus—a self-expanding, non-circular valve designed for the tricuspid annulus—with robotic delivery, potentially improving success rates over manual implantation
This first-in-human result positions Jenscare at the forefront of robotic structural heart therapy, a nascent but high-growth segment.
Strategic Implications
- Pipeline Acceleration: Data will support regulatory filings in China (NMPA) and CE Mark preparation
- Global Differentiation: One of only a handful of companies worldwide developing dedicated robotic TTVR systems
- Commercial Synergy: Leverages Jenscare’s existing LuX-Valve franchise in pulmonary and tricuspid indications
If scaled successfully, iJensRobo could become the standard platform for complex right-heart interventions, analogous to how robotics transformed mitral valve repair.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory pathways, clinical adoption, and technological scalability. Actual outcomes may vary due to trial expansion results, regulatory feedback, and competitive developments.-Fineline Info & Tech